Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5745)	2/26/2002 12:36:02 AM
From: Jibacoa	Read Replies (1) of 52153

It seems that with the good news coming out from the different drug-eluting stent trials (showing next to zero restenosis at 6 months )there is going to be some time before finding out which one will be the best product. I was looking at some of the reports from Brazil (RAVEL), Germany (TAXUS) and Europe (ELUTES) and it seems the RAVEL results using sirolimus were better than the TAXUS and ELUTES using paclitaxel. Any opinions on which one will be first approved by the FDA ? It also seems that KOSP is going to have a hard time promoting its Niacin-statin combination (Advicor) and will see if the stock will be able hold the support at 19 level. BMY is going to have a hard time with the FDA approval of their Pravastatin-Aspirin combination. It seems AZN's Rosuvastatin (Crestor) is the most potent statin so far and AZN's stock appears headed to test its September H at the 53 level.<g> May be a good combination would be Rosuvastatin with SGP's Ezetimibe since SGP's product inhibits cholesterol absorption and re-absorption.<g> SGP's stock seems to have found support this month at the 31 level.<g> RAGL Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next